cd18

Dexamethasone is a glucocorticoid receptor agonist and IL receptor modulator with anti-inflammatory, immunosuppressive, and apoptosis-inducing activities. It inhibits the production of inflammatory miRNA-155 exosomes in macrophages, significantly reduces inflammatory cytokine expression in neutrophils and monocytes, suppresses LPS-induced macrophage inflammation, and induces autophagy. It is commonly used to induce animal models of depression, muscle atrophy, and hypertension, and holds potential in COVID-19 research.

J-113863 is also a potent antagonist of the human CCR3 (IC50 of 0.58 nM) , but a weak antagonist of the mouse CCR3 (IC50 of 460 nM). J-113863 is inactive against CCR2, CCR4 and CCR5, as well as the LTB4 or TNF-α receptors. Anti-inflammatory effect. J-113863 is a potent and selective CCR1 (CD18) antagonist with IC50 values of 0.9 nM and 5.8 nM for human and mouse CCR1 receptors, respectively.

Leukadherin-1 is an allosteric activator of CD11b/CD18. Increasing CD11b/CD18-dependent cell adhesion to fibrinogen, Decreasing leukocyte motility and transendothelial migration; reduces inflammation.

Anti-Mouse CD18 Antibody (M18/2) is a rat-derived IgG2a, κ antibody inhibitor that targets mouse CD18.

Anti-CXCR4/CD184 Antibody represents a highly specialized monoclonal antibody specifically engineered to target the human C-X-C chemokine receptor type 4 (CXCR4) with exceptional binding affinity. It effectively facilitates the measurable blockade of the CXCL12/CXCR4 signaling axis across various preclinical experimental models to evaluate the modulation of cellular chemotaxis, hematopoietic stem cell mobilization, and the inhibition of tumor metastasis during strictly monitored laboratory observation periods and functional cell migration assays.

Anti-CXCR3/GPR9/CD183 Antibody is a potent monoclonal antibody targeting the chemokine receptor CXCR3, acting by competitively blocking the binding of pro-inflammatory chemokines (such as CXCL10) to the receptor's extracellular domain. The compound is an essential tool for investigating effector T cell recruitment, the pathogenesis of autoimmune diseases, and tumor immune microenvironment remodeling, aiming to inhibit excessive inflammatory cell infiltration by intervening in the CXCR3-mediated signaling axis.

The Anti-Mouse CXCR3/CD183 Antibody (CXCR3-173) is an IgG antibody inhibitor derived from a hamster originating from the United States, specifically targeting mouse CXCR3/CD183.

Anti-CD185/CXCR5 Antibody is a specialized monoclonal antibody target the C-X-C chemokine receptor type 5 protein, inhibition of ligand-induced intracellular signaling and cellular chemotaxis across various preclinical experimental models to modulate immune cell infiltration and tumor progression.

Ulocuplumab-MMAE , an Anti-CXCR4/CD184 Reference Antibody, is produced in CHO cells. This antibody features a human IgG1 (huIgG1) heavy chain and a human kappa (hukappa) light chain. Its molecular weight is predicted to be 145.78 kDa.

4F-Docetaxel (4FDT) is a fluorinated derivative of docetaxel that exhibits significant antitumor activity against hepatocellular carcinoma (HCC) and is suitable for research on liver cancer.

Cyclosporin A is a natural product and an active fungal metabolite, classified as a cyclic polypeptide immunosuppressant. It binds to cyclophilin and inhibits the activity of calcineurin (IC₅₀ = 7 nM) as well as CD11a/CD18 adhesion molecules. It is commonly used to induce uremia models.

Rovelizumab (Hu23F2G) is a humanized monoclonal antibody targeting the cell adhesion molecule CD11/CD18. It inhibits overactive leukocytes during shock and may be used in studies of multiple sclerosis (MS), hemorrhagic shock, myocardial infarction, and stroke.

Erlizumab is a monoclonal antibody against Integrin b2/ITGB2/CD18 subunit of Mac-1 receptor. By blocking the interaction between CD18 on the surface of leukocytes and adhesion molecules of vascular endothelial cells, Erlizumab can effectively inhibit the recruitment and infiltration of inflammatory cells, thus alleviating the tissue damage in myocardial ischemia-reperfusion injury.

Dexamethasone-D3-1 is a deuterium-labeled form of Dexamethasone. Dexamethasone (T1076) (Hexadecadrol) acts as an agonist of the glucocorticoid receptor and effectively reduces the expression of CD11b, CD18, and CD62L on neutrophils, as well as CD11b and CD18 on monocytes. It holds potential for research on COVID-19. In LPS-induced macrophage inflammatory responses, Dexamethasone (T1076) inhibits the production of exosomes containing inflammatory miRNA-155.

Cyclosporin A-D4 is a deuterated form of Cyclosporin A. Cyclosporin A (Cyclosporine A) functions as an immunosuppressant by binding to cyclophilin and inhibiting calcineurin activity with an IC50 value of 7 nM. It also obstructs the adhesion molecules CD11a/CD18.

Cyclosporin A acetate-D4 is a deuterium-labeled form of Cyclosporin A. Cyclosporin A (Cyclosporine A) is an immunosuppressive agent that binds to cyclophilin, inhibiting the activity of protein phosphatase 2B (PP2B/calcineurin) with an IC50 value of 7 nM. Additionally, Cyclosporin A impedes the adhesion molecules CD11a/CD18.

Dexamethasone-4,6α,21,21-D4 is the deuterated derivative of Dexamethasone-4,6α,21,21. Dexamethasone (T1076) (Hexadecadrol) functions as an agonist of the glucocorticoid receptor. It notably reduces the expression of CD11b, CD18, and CD62L on neutrophils, as well as CD11b and CD18 on monocytes. Dexamethasone (T1076) shows potential for research related to COVID-19.

Cyclosporin A-13C2,D4 is a 13C-labeled form of Cyclosporin A. Cyclosporin A (T0945) is an immunosuppressant that binds to cyclophilin, inhibiting protein phosphatase 2B (PP2B/calcineurin) with an IC50 of 7 nM, and also suppresses the CD11a/CD18 adhesion molecules.

Cyclosporin A-D12 is a deuterium-labeled form of Cyclosporin A. Cyclosporin A (T0945) (Cyclosporine A) functions as an immunosuppressant by binding to cyclophilin and inhibiting protein phosphatase 2B (PP2B/calcineurin) with an IC50 value of 7 nM. It also inhibits the adhesion molecule CD11a/CD18.

Cyclosporin A (Standard) is a reference standard for research and analysis in studies involving Cyclosporin A. Cyclosporin A is a natural product and an active fungal metabolite, classified as a cyclic polypeptide immunosuppressant. It binds to cyclophilin and inhibits the activity of calcineurin (IC₅₀ = 7 nM) as well as CD11a/CD18 adhesion molecules. It is commonly used to induce uremia models.

Dexamethasone-4,6α,21,21-D4 (Standard) is a reference standard of Dexamethasone-4,6α,21,21-D4 intended for quantitative analysis, quality control, and related biochemical research applications. Dexamethasone-4,6α,21,21-d4 is the deuterated derivative of Dexamethasone-4,6α,21,21. Dexamethasone (Hexadecadrol) functions as an agonist of the glucocorticoid receptor. It notably reduces the expression of CD11b, CD18, and CD62L on neutrophils, as well as CD11b and CD18 on monocytes. Dexamethasone shows potential for research related to COVID-19.